Study Shows Significant Improvements In Peak Bloodstream Estradiol Delivery Using Lexaria's DehydraTECH

Lexaria Bioscience Corp (NASDAQ:LEXX) announces that its animal study HOR-A22-1 has been completed, showing significant enhancement in the oral delivery of the estrogen hormone estradiol.

The DehydraTECH-estradiol formulation achieved an average peak concentration in the bloodstream (Cmax) of 5.65ng/mL, roughly nine times (900%) higher than that achieved with the control formulation at only 0.63 ng/mL. 

Also Read: Lexaria Discovers Potential Novel Mechanism From Hypertension Study Of Processed CBD.

This revealed that levels of the estrone metabolite were also significantly higher, comparing an average Cmax of 6.49 ng/mL with the DehydraTECH formulation to only 0.302 ng/mL achieved with the control, representing greater than a twenty-fold (2,000%) improvement in delivery.

Also, the total estradiol and estrone recovery in the blood plasma over time or the Area Under the Curve (AUC) was dramatically higher at 3.9 hr·ng/mL for estradiol and 32.6hr·ng/mL for the estrone with the DehydraTECH composition versus being non-detectable below the lower limit of quantitation of the assay (i.e., 0.25 ng/mL) with the control in both instances. 

This means that the AUC findings were at least fifteen times (1,500%) greater than the control for estradiol and over one hundred and twenty-five times (12,500%) greater for estrone.

Price Action: LEXX shares are up 13.70% at $0.84 on the last check Thursday.